Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Completed 3Withdrawn 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Other neoplasm 1

Conditions

Lung Neoplasms 4Pulmonary Disease, Chronic Obstructive 1Precancerous Conditions 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Iloprost × Thoracic × Clear all
NCT05411107 2024-05-17

Oral Iloprost for the Prevention of Lung Cancer In Former Smokers

National Cancer Institute (NCI)

Phase 2 Withdrawn
Thoracic

Lung Neoplasms, Pulmonary Disease, Chronic Obstructive

NCT02237183 2023-11-28

Iloprost in Preventing Lung Cancer in Former Smokers

National Cancer Institute (NCI)

Phase 1 Completed
34 enrolled
Thoracic

Lung Neoplasms

NCT00084409 2020-05-14

Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease

University of Colorado, Denver

Phase 2 Completed
152 enrolled 18 charts
Other neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Precancerous Conditions

NCT02784899 2018-06-20

Effect of Iloprost on Pulmonary Oxygenation in Patients With Low Diffusing Capacity During One-lung Ventilation

Yonsei University

Phase NA Completed
40 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡